Daily22m
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis
Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
Equillium announces itolizumab study achieves secondary endpoint
Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
Equillium stock rallies 26% on itolizumab study data
Shares of Equillium (NASDAQ:EQ) soared 26% Thursday after the company and partner Biocon reported positive topline results from a Phase 2 study of the drug itolizumab in the treatment of moderate to ...
Equillium reports positive Phase 2 ulcerative colitis study data
Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...
Nature4y
Restoring immune balance: Targeting CD6 to treat autoimmune and inflammatory disease
Equillium’s itolizumab downregulates T effector cell activity and trafficking to tissues. It is currently being tested against acute graft-vs-host disease (aGVHD), lupus nephritis, and ...
Pharmabiz2h
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...